SEC filing · 8-K

Akari Therapeutics Plc: Executive or director change

Akari Therapeutics amended its CEO agreement to increase executive compensation and equity grants.

Filed October 1, 2026

Neutral news

What happened

On September 29, 2026, Akari Therapeutics amended its employment agreement with CEO Abizer Gaslightwala.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Akari Therapeutics Plc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.